Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

References

• LawrenceRCHochbergMCKelseyJLEstimates of the prevalence of selected arthritic and musculoskeletal diseases in the United StatesJ Rheumatol19891644274412746583
   PubMed Web of Science ®Google Scholar
• FernandezDKirouKAWhat causes lupus flares?Curr Rheumatol Rep20161831426951252
   PubMed Web of Science ®Google Scholar
• CartellaSCavazzanaICeribelliAInverardiFTincaniAFranceschiniFEvaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosusAutoimmunity201346636336823706114
   PubMed Web of Science ®Google Scholar
• CooperGSDooleyMATreadwellELSt ClairEWGilkesonGSRisk factors for development of systemic lupus erythematosus: allergies, infections, and family historyJ Clin Epidemiol2002551098298912464374
   PubMed Web of Science ®Google Scholar
• BuyonJPPetriMAKimMYThe effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trialAnn Intern Med200514212 Pt 195396215968009
   PubMed Web of Science ®Google Scholar
• HahnBHEblingFSinghRRSinghRPKarpouzasGLa CavaACellular and molecular mechanisms of regulation of autoantibody production in lupusAnn N Y Acad Sci2005105143344116126985
   PubMed Web of Science ®Google Scholar
• ParksCGCooperGSOccupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studiesLupus2006151172873617153843
   PubMed Web of Science ®Google Scholar
• WongMTsaoBPCurrent topics in human SLE geneticsSpringer Semin Immunopathol20062829710716941108
   PubMed Web of Science ®Google Scholar
• MorawskiPABollandSExpanding the B Cell-Centric View of Systemic Lupus ErythematosusTrends Immunol201738537338228274696
   PubMed Web of Science ®Google Scholar
• Guidelines for referral and management of systemic lupus erythematosus in adultsAmerican College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus GuidelinesArthritis Rheum19994291785179610513791
   PubMedGoogle Scholar
• BertsiasGIoannidisJPBoletisJEULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including TherapeuticsAnn Rheum Dis200867219520517504841
   PubMed Web of Science ®Google Scholar
• HahnBHMcMahonMAWilkinsonAAmerican College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care Res2012646797808
   PubMed Web of Science ®Google Scholar
• Cobo-IbáñezTLoza-SantamaríaEPego-ReigosaJMEfficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic reviewSemin Arthritis Rheum201444217518524830791
   PubMed Web of Science ®Google Scholar
• WilhelmusSBajemaIMBertsiasGKLupus nephritis management guidelines comparedNephrol Dial Transplant201631690491325920920
   PubMed Web of Science ®Google Scholar
• AkhavanPSSuJLouWGladmanDDUrowitzMBFortinPRThe early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosusJ Rheumatol201340683184123588942
   PubMed Web of Science ®Google Scholar
• SugaiDYGustafsonCJDe LucaJFTrends in the outpatient medication management of lupus erythematosus in the United StatesJ Drugs Dermatol201413554555224809877
   PubMed Web of Science ®Google Scholar
• PohYJBaptistaBD’CruzDPSubcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administrationExpert Rev Clin Immunol2017131092593828847197
   PubMed Web of Science ®Google Scholar
• MoorePABelvedereOOrrABLyS: member of the tumor necrosis factor family and B lymphocyte stimulatorScience1999285542526026310398604
   PubMed Web of Science ®Google Scholar
• WuYBressetteDCarrellJATumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLySJ Biol Chem200027545354783548510956646
   PubMed Web of Science ®Google Scholar
• ZhangJRoschkeVBakerKPCutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosusJ Immunol2001166161011123269
   PubMed Web of Science ®Google Scholar
• StohlWMetyasSTanSMB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsArthritis Rheum200348123475348614673998
   PubMed Web of Science ®Google Scholar
• CollinsCEGavinALMigoneTSHilbertDMNemazeeDStohlWB lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levelsArthritis Res Ther200681R616356193
   PubMed Web of Science ®Google Scholar
• PetriMStohlWChathamWAssociation of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis Rheum20085882453245918668552
   PubMed Web of Science ®Google Scholar
• BakerKPEdwardsBMMainSHGeneration and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorArthritis Rheum200348113253326514613291
   PubMed Web of Science ®Google Scholar
• HalpernWGLappinPZanardiTChronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effectsToxicol Sci200691258659916517838
   PubMed Web of Science ®Google Scholar
• StohlWHiepeFLatinisKMBelimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusArthritis Rheum20126472328233722275291
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFPetriMACerveraRBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnn Rheum Dis20127181343134922337213
   PubMed Web of Science ®Google Scholar
• ManziSSánchez-GuerreroJMerrillJTEffects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnn Rheum Dis201271111833183822550315
   PubMed Web of Science ®Google Scholar
• FanouriakisAAdamichouCKoutsovitiSLow disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational studySemin Arthritis Rheum Epub2018223
   Web of Science ®Google Scholar
• FurieRStohlWGinzlerEMBiologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Res Ther2008105R10918786258
   PubMed Web of Science ®Google Scholar
• WallaceDJStohlWFurieRAA phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Rheum20096191168117819714604
   PubMed Web of Science ®Google Scholar
• NavarraSVGuzmánRMGallacherAEEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
   PubMed Web of Science ®Google Scholar
• FurieRPetriMZamaniOA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
   PubMed Web of Science ®Google Scholar
• GinzlerEMWallaceDJMerrillJTDisease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusJ Rheumatol201441230030924187095
   PubMed Web of Science ®Google Scholar
• ZhangFBaeSCBassDA pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South KoreaAnn Rheum Dis201877335536329295825
   PubMed Web of Science ®Google Scholar
• PascoeKLoboscoSBellDPatient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical PracticeClin Ther20173991811182628803702
   PubMed Web of Science ®Google Scholar
• CaiWWFiscellaMChenCZhongZJFreimuthWWSubichDCBioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy SubjectsClin Pharmacol Drug Dev20132434935727121939
   PubMed Web of Science ®Google Scholar
• ShidaYTakahashiNSakamotoTInoHEndoAHiramaTThe pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteersJ Clin Pharm Ther20143919710124117862
   PubMed Web of Science ®Google Scholar
• YapaSWRothDGordonDStruemperHComparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 programLupus201625131448145527072354
   PubMed Web of Science ®Google Scholar
• StruemperHMurtaughTGilbertJRelative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy SubjectsClin Pharmacol Drug Dev20165320821527163500
   PubMed Web of Science ®Google Scholar
• SheikhSZHammerAEFoxNLEvaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosusInt J Clin Pharmacol Ther2016541191492227668697
   PubMed Web of Science ®Google Scholar
• StruemperHThaparMRothDPopulation Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus ErythematosusClin Pharmacokinet201857671772828887801
   PubMed Web of Science ®Google Scholar
• StohlWSchwartingAOkadaMEfficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled StudyArthritis Rheumatol20176951016102728118533
   PubMed Web of Science ®Google Scholar
• DoriaAStohlWSchwartingAEfficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypoco-mplementemic Patients With Systemic Lupus ErythematosusArthritis Rheumatol20187081256126429671280
   PubMed Web of Science ®Google Scholar
• DoriaABassDSchwartingAA 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosusLupus20182791489149829807477
   PubMed Web of Science ®Google Scholar
• RamachandranSParksDKurtineczMRothDAAlfonso-CristanchoRAn indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activityJ Comp Eff Res20187658159329692179
   PubMed Web of Science ®Google Scholar
• Benlysta^® (belimumab) [prescribing information]Rockville (MD)GlaxoSmithKline Ltd2017
   Google Scholar
• FalangaMCanzonaAMazzoniDPreference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLEJ Patient Exp2018237437351877081
   Google Scholar
• Dashiell-AjeEHardingGPascoeKDevriesJBerryPRamachandranSPatient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus ErythematosusPatient201811111912928956281
   PubMedGoogle Scholar